Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522833 · ClinicalTrials.gov registry record
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
A clinical trial, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- 27
- Enrollment target
NCT01522833: Completed study, sponsored by SCRI Development Innovations.
NCT01522833 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522833 has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.
Primary Outcome
To describe patient demographic characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt. Demographic characteristics include age, race,ethnicity, date of initial diagnosis, age at initial diagnosis, location of biopsy at diagnosis, extent of disease with description and location of metastatic sites, histology,and smoking history.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-02 |
What the finished NCT01522833 record still lists
NCT01522833 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01522833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01522833 about?
NCT01522833 is a clinical study titled "Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer". With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the...
What is the current status of trial NCT01522833?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2012-10. Estimated completion is 2015-02.
Who is sponsoring clinical trial NCT01522833?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia